Business
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2024
MISSISSAUGA, Ontario, March 13, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”,...
About this update from Biosyent Inc.
[{"type":"text","content":"BioSyent Releases Financial Results for Fourth Quarter and Full Year 2024\n\n\n\n MISSISSAUGA, Ontario, March 13, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2024. Key highlights include:\n \n\n\n\n (CAD)\n \n\n\n Q4 2024\n \n\n\n\n\n % Change\n \n vs.\n \n\n\n Q4 2023\n \n\n\n\n\n\n FY 2024\n \n\n\n\n % Change\n \n vs.\n \n\n\n FY 2023\n \n\n\n\n\n\n Canadian Pharma Sales\n \n\n\n\n 8,546,451\n \n\n\n\n +7\n \n\n\n\n %\n \n\n\n\n 32,931,149\n \n\n\n\n +11\n \n\n\n\n %\n \n\n\n\n\n\n International Pharma Sales\n \n\n\n\n 176,734\n \n\n\n\n +223\n \n\n\n\n %\n \n\n\n\n 929,975\n \n\n\n\n -11\n \n\n\n\n %\n \n\n\n\n\n\n Legacy Business Sales\n \n\n\n\n 73,499\n \n\n\n\n -68\n \n\n\n\n %\n \n\n\n\n 1,169,773\n \n\n\n\n +18\n \n\n\n\n %\n \n\n\n\n\n\n Total Company Sales\n \n\n\n\n 8,796,684\n \n\n\n\n +6\n \n\n\n\n %\n \n\n\n\n 35,030,897\n \n\n\n\n +11\n \n\n\n\n %\n \n\n\n\n\n\n EBITDA\n \n\n\n 1\n \n\n\n\n\n 2,241,112\n \n\n\n\n +36\n \n\n\n\n %\n \n\n\n\n 9,343,012\n \n\n\n\n +18\n \n\n\n\n %\n \n\n\n\n\n\n Net Income After Taxes (NIAT)\n \n\n\n\n 1,613,194\n \n\n\n\n +11\n \n\n\n\n %\n \n\n\n\n 7,270,104\n \n\n\n\n +13\n \n\n\n\n %\n \n\n\n\n\n\n Fully Diluted EPS\n \n\n\n\n 0.14\n \n\n\n\n +17\n \n\n\n\n %\n \n\n\n\n 0.62\n \n\n\n\n +16\n \n\n\n\n %\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Return on Equity for FY 2024 was 21% as compared to 19% for FY 2023\n \n\n During FY 2024, repurchased for cancellation a total of 492,300 common shares under Normal Course Issuer Bid (NCIB)\n \n\n Paid quarterly cash dividends of $0.045 per common share on March 15, 2024, June 15, 2024, September 15, 2024, and December 16, 2024\n \n\n Declared subsequent cash dividend of $0.05 per common share to be paid on March 14, 2025\n \n\n In September 2024, acquired Tibelia\n \n ®\n \n / Tibella\n \n ®\n \n (tibolone) global rights and related assets\n \n\n\n\n “BioSyent ended 2024 with continued growth from across our Canadian pharmaceutical portfolio in the fourth quarter, reporting our highest-ever quarterly Canadian pharmaceutical sales,” commented Mr. René Goehrum, President and CEO of BioSyent. “During the fourth quarter, we also transitioned the global distribut...